Literature DB >> 18374884

Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure.

Gayathri Kamalakkannan1, Christopher M Petrilli, Isaac George, John LaManca, Brooke T McLaughlin, Elizabeth Shane, Donna M Mancini, Simon Maybaum.   

Abstract

Clenbuterol, a beta(2)-agonist with potent anabolic properties, has been shown to improve skeletal muscle function in healthy subjects, and in high doses, promotes cardiac recovery in patients with left ventricular assist devices. In a small, randomized controlled study, we investigated the effect of clenbuterol on skeletal muscle function, cardiac function, and exercise capacity in patients with chronic heart failure. Clenbuterol was well tolerated and led to a significant increase in both lean mass and the lean/fat ratio. Maximal strength increased significantly with both clenbuterol (27%) and placebo (14%); however, endurance and exercise duration decreased after clenbuterol. Prior data support combining exercise training with clenbuterol to maximize performance, and on-going studies will evaluate this approach.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18374884     DOI: 10.1016/j.healun.2008.01.013

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  17 in total

Review 1.  Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.

Authors:  Joaquim Gea; Carme Casadevall; Sergi Pascual; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

2.  Adjunctive β2-agonist treatment reduces glycogen independently of receptor-mediated acid α-glucosidase uptake in the limb muscles of mice with Pompe disease.

Authors:  Benjamin L Farah; Lauran Madden; Songtao Li; Sierra Nance; Andrew Bird; Nenad Bursac; Paul M Yen; Sarah P Young; Dwight D Koeberl
Journal:  FASEB J       Date:  2014-01-21       Impact factor: 5.191

Review 3.  Managing sarcopenia and its related-fractures to improve quality of life in geriatric populations.

Authors:  Tetsuro Hida; Atsushi Harada; Shiro Imagama; Naoki Ishiguro
Journal:  Aging Dis       Date:  2013-11-26       Impact factor: 6.745

4.  Correction of Biochemical Abnormalities and Improved Muscle Function in a Phase I/II Clinical Trial of Clenbuterol in Pompe Disease.

Authors:  Dwight D Koeberl; Laura E Case; Edward C Smith; Crista Walters; Sang-Oh Han; Yanzhen Li; Wei Chen; Christoph P Hornik; Kim M Huffman; William E Kraus; Beth L Thurberg; David L Corcoran; Deeksha Bali; Nenad Bursac; Priya S Kishnani
Journal:  Mol Ther       Date:  2018-07-05       Impact factor: 11.454

5.  Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease.

Authors:  Songtao Li; Baodong Sun; Mats I Nilsson; Andrew Bird; Mark A Tarnopolsky; Beth L Thurberg; Deeksha Bali; Dwight D Koeberl
Journal:  FASEB J       Date:  2012-09-19       Impact factor: 5.191

6.  Myocardial recovery with left ventricular assist devices.

Authors:  Maya Guglin; Leslie Miller
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

Review 7.  Muscle wasting and cachexia in heart failure: mechanisms and therapies.

Authors:  Stephan von Haehling; Nicole Ebner; Marcelo R Dos Santos; Jochen Springer; Stefan D Anker
Journal:  Nat Rev Cardiol       Date:  2017-04-24       Impact factor: 32.419

Review 8.  Adrenergic nervous system in heart failure: pathophysiology and therapy.

Authors:  Anastasios Lymperopoulos; Giuseppe Rengo; Walter J Koch
Journal:  Circ Res       Date:  2013-08-30       Impact factor: 17.367

9.  Randomized, double-blind, and placebo-controlled trial of clenbuterol in denervated muscle atrophy.

Authors:  Guang-Liang Jiang; Yu-Dong Gu; Li-Yin Zhang; Li-Ying Shen; Cong Yu; Jian-Guang Xu
Journal:  ISRN Pharm       Date:  2011-08-15

Review 10.  The impact of catecholamines on skeletal muscle following massive burns: Friend or foe?

Authors:  Elizabeth Blears; Evan Ross; John O Ogunbileje; Craig Porter; Andrew J Murton
Journal:  Burns       Date:  2021-02-02       Impact factor: 2.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.